Ключевые слова
Как цитировать
Аннотация
Цель работы - систематизация и обобщение данных научных исследований, имеющихся в современной литературе, о применении лекарственного препарата руксолитиниб у пациентов с первичным миелофиброзом (ПМФ) до аллогенной трансплантации гемо-поэтических стволовых клеток (аллоТГСК) для улучшения её результатов. В обзор включены данные зарубежных и отечественных статей, найденные в базах данных PubMed и Elibrary.ru, описывающие результаты применения руксолитиниба у пациентов с ПМФ до аллоТГСК, включая клинические случаи, оригинальные научные исследования и обзоры. Сообщается, что терапия руксолитинибом является безопасной, позволяет снизить летальность в раннем посттрансплантационном периоде, уменьшает частоту развития острой и хронической реакции «трансплантат против хозяина», снижает вероятность рецидива. Клиническое улучшение на фоне терапии руксолитинибом в период до трансплантации можно рассматривать прогностически благоприятным фактором.
Библиографические ссылки
Teo S, Tiedt R, Passweg JR.et al. A Gain-of-Function Mutation of JAK2. NEJM. 2005;352(17): 1779-1790.
Plosker GL. Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis. Drugs. 2015;75:297-308. DOI: 10.1007/s40265-015-0351-8
Verstovsek S. Changing myelofibrosis’s natural course at last. Blood. 2014;123(12):1776-7.
Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012;19(26): 4399-413.
Santos FP, Verstovsek S. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation? Anticancer Agents Med Chem. 2012;12(9):1098-109.
Oh ST, Gotlib J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol. 2010;3(3):323- 37.
Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-82.
Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-405.
Клименко С.В., Мищенюк О.Ю. Эффективность и безопасность руксолитиниба при лечении миелофиброза по данным исследований COMFORT I и COMFORT II. Здоровье Украины. Онкогематология. 2015; 21-22.
Verstovsek S, Mesa RA, Gotlib J, et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New Eng J Med. 2012: March 1;366:799-807.
Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New Eng J Med. 2012: March 1;3бб:787-98.
Bradley EC, Erickson-Viitanen S, Vaddi K et al. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. NEJM. 2010;362(15): 1117-1127.
Verstovsek S, Mesa RA, Gotlib J et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4): 479-488.
Cervantes F. How I treat myelofibrosis. Blood. 2014;124(17): 2635-42.
Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COM-FORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013; 122(25): 4047-53.
Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8): 1701-7.
Harrison CN, Bennett M. Orphan drugs for myelofibrosis. Expert Opin Orphan Drugs. 2014;2(4):391-405.
Mascarenhas J. Rationale for combination therapy in myelofibrosis. Best Pract Res Clin Haematol. 2014;27(2):197-208.
Stubig T, Alchalby H, Ditschkowski M, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia. 2014;28(8):1736-8.
Jaekel N, Behre G, Behning A, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant. 2014;49(2):179-84.
Qureshi MR, MacLean C, McMullin MF, et al. Management of myelofibrosis: a survey of current practice in the United Kingdom. J Clin Pathol. 2012;65(12):1124-7.
Ballen K. How to manage the transplant question in myelofibrosis. Blood Cancer J. 2012;2(3):e59.
Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012; 120: 1367-1379.
Барабанщикова М.В., Морозова Е.В., Байков В.В. и др. Аллогенная трансплантация гемопоэтических стволовых клеток при миелофиброзе. Клиническая онкогематология. 2016;9(3):279-86. DOI: 10.21320/2500-2139-2016-9-3-279-286
Akpek G, Pasquini MC, Logan B. et al. Effects of spleen status on early outcomes after hematopoietic cell trans plantation. Bone Marrow Transplant. 2013;48(6): 825831.
Ballen KK, Shrestha S., Sobocinski KA. et al. Outcome of transplantation for Myelofibrosis. Biol. Blood Marrow Transplant. 2010;16(3): 358-367.
Kroger N., Holler E., Kobbe G. et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26): 5264-5270.
Rondelli D., Goldberg JD, Isola L. et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014;124(7): 1183-1191.
Bacigalupo A., Soraru M., Dominietto A., Pozzi S., Geroldi S., Van Lint MT et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010; 45: 458-463.
Matsubara E., Yamanouchi J., Kitazawa R., Azuma T., Fujiwara H., Hato T., Yasukawa M. Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis. Case Rep Hematol. 2016; 2016: 8751329.
Robin M., Zine M., Chevret S., Meignin V., Munoz-Bongrand N., Moatti H., Xhaard A., Sicre de Fontbrune F., Peffault de Latour R., Sarfati E., Socie G. The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017; 23(6): 958-64.
Kadir S., Christopeit M., Wulf G., Wagner E., Bornhauser M., Schroeder T., Crysandt M., Mayer K., Jonas J., Stelljes M., Badbaran A., Ayuketang Ayuk F., Triviai I., Wolf D., Wolschke C., Kroger N. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur J. Haematol. 2018 Sep;101(3):305-317. Epub 2018 Jul 4. DOI: 10.1111/ejh.13099
Ballinger TJ, Savani BN, Gupta V., Kroger N., Mohty M. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis. Eur J. Haematol. 2015; 94(2):115-119.
Shanavas M., Messner HA, Atenafu EG, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. Bone Marrow Transplant 49: 1162-1169, 2014.
Spoeri S., Mathew NR, Bscheider M., et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 123: 3832- 3842, 2014.
Lavi N., Rowe JM, Zuckerman T. Allogeneic stemcell transplantation for myelofibrosis. Curr opin Hematol. 2017 Nov;24(6):475-480.
Shanavas M., Popat U., Michaelis L.C. et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant. 2016; 22(3): 432-40.
Robin M., Francois S., Huynh A. et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by Goelams-FIM in collaboration with the Sfgmtc. Blood 2013; 122: 306.
Hanif A., Hari P.N., Atallah E. et al. Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. Bone Marrow Transplant. 2016 Apr;51(4):617-8.
Kroger N., Shahnaz Syed Abd Kadir S., Zabelina T., Badbaran A., Christopeit M., Ayuk F., Wolschke C. Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 May 22. pii: S1083-8791(18)30295-7. DOI: 10.1016/j.bbmt.2018.05.023
Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013;143: 1478-1479.
Goldberg RA, Reichel E., Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N. Engl J. Med. 2013;369: 681-683.
Colomba C., Rubino R., Siracusa L., et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes. 2012;5: 552.
Heine A., Held SA, Daecke SN, Wallner S. et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013; 122(7): 1192-202.
Heine A., Brossart P., Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013; 122(23): 3843-4.
Chatterjee B., Rqieh U., Greaves P., Piras D., Firth J., Saja K. Sweet syndrome as terminal event in ruxolitinib-treated myelofibrosis. Br J. Haematol. 2015;169: 307.
Sakoda T., Kanamitsu X. Mori Y. et al. Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation. Intern Med. 2017 Sep 15;56(18):2481-2485.
Parampalli Yajnanarayana S., Stubig T., Cornez I., et al. JAK1/2 inhibition impairs T. cell function in vitro and in patients with myeloproliferative neoplasms. Br J. Haematol. 2015;169:824-833.
Zeiser R., Burchert A., Lengerke C. et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015; 29(10): 2062-2068.
Барабанщикова М.В., Морозова Е.В., Власова Ю.Ю., Байков В.В., Зубаровская Л.С., Афанасьев Б.В. Применение ингибитора JAK1 и JAK2 руксолитиниба в качестве пред- и пост-трансплантационной терапии пациентов с миелофиброзом. Ученые записки СПбГМУ им. акад. И. П. Павлова. 2016; 23(1): 43-46.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2019